TransMedics delivered a robust third quarter in 2025, with total revenue increasing by 32% year-over-year to $143.8 million. The company achieved a net income of $24.3 million, or $0.66 per diluted share, demonstrating strong profitability and operational efficiency.

TransMedics delivered a robust second quarter in 2025, achieving $157.4 million in total revenue, a 38% increase year-over-year, and a net income of $34.9 million. The growth was primarily driven by increased utilization of the Organ Care System (OCS) in Liver and Heart through the National OCS Program (NOP) and related service revenue, supported by the expansion of their aviation fleet.

TransMedics delivered strong top and bottom-line financial results in Q1 2025, with total revenue increasing 48% year-over-year to $143.5 million and net income reaching $25.7 million. The company also raised its full-year 2025 revenue guidance.

TransMedics reported a 50% increase in total revenue to $121.6 million in Q4 2024, with net income reaching $6.9 million. For the full year, revenue grew 83% to $441.5 million, and net income was $35.5 million.

TransMedics reported a strong third quarter with a 64% increase in revenue compared to the previous year, driven by increased utilization of the Organ Care System and logistics services. The company achieved net income of $4.2 million, a significant improvement from the net loss in the same quarter of the previous year. TransMedics is on track to meet its target of 10,000 OCS transplant cases per year in the U.S. by 2028 and expects full-year revenue to be in the range of $425 million to $445 million.

TransMedics reported a strong second quarter in 2024, marked by a 118% increase in revenue compared to the previous year. The growth was fueled by the sustained momentum of OCS NOP and the company's transplant logistics network. The company is raising its full year 2024 revenue guidance to be in the range of $425 million to $445 million.

TransMedics reported a strong first quarter with a 133% increase in revenue compared to the previous year, reaching $96.9 million. The company also generated a net income of $12.2 million, or $0.35 per fully diluted share. They are raising their full year 2024 revenue guidance to be in the range of $390 million to $400 million.

TransMedics reported a 159% increase in revenue to $81.2 million for the fourth quarter of 2023, driven by increased utilization of the OCS through the National OCS Program (NOP) and the addition of TransMedics logistics services. The company generated a net income of $4.0 million, or $0.12 per share, compared to a net loss in the same quarter of the previous year.

TransMedics reported a significant increase in revenue for the third quarter of 2023, driven by greater utilization of their NOP across all three OCS products and the addition of logistics and aviation revenue, but experienced a net loss due to non-recurring acquisition-related costs.

TransMedics reported a strong second quarter with a 156% increase in revenue compared to the previous year. The growth was primarily driven by the increased utilization of the National OCS Program. The company also updated its full-year revenue guidance to $180 million to $190 million.

TransMedics reported a strong first quarter with a 162% increase in revenue compared to the previous year, driven primarily by the adoption of the National OCS Program (NOP) and increased sales of OCS Liver and OCS Heart. The company is updating its full year 2023 revenue guidance to be in the range of $160 million to $170 million.

TransMedics reported a significant increase in revenue for Q4 2022, driven by the expansion of their National OCS Program (NOP). Total revenue reached $31.4 million, a 225% increase compared to Q4 2021. The company's net loss decreased to $6.7 million from $12.7 million in the same quarter of the previous year.

TransMedics reported a significant increase in net revenue for Q3 2022, reaching $25.7 million, a 378% increase compared to Q3 2021. This growth was primarily driven by the adoption of the OCS technology and the National OCS Program (NOP). The company has updated its full-year 2022 revenue guidance to $80 million to $85 million.

TransMedics reported a 151% increase in net revenue for the second quarter of 2022, reaching $20.5 million. The growth was primarily driven by increased commercial sales of the OCS™ Heart and OCS™ Liver in the United States. The company also updated its full year 2022 net revenue guidance to be in the range of $67 million to $75 million.

TransMedics reported a strong first quarter with net revenue of $15.9 million, a 125% increase compared to the same period in 2021. The growth was primarily driven by increased commercial sales of OCS Heart and OCS Liver in the United States. The company is updating its full year 2022 net revenue guidance to be in the range of $59 million to $65 million.

TransMedics reported a 27% increase in net revenue for Q4 2021, reaching $9.7 million, driven by the commercial launch of OCS Heart and OCS Liver in the United States. The gross margin improved to 72%, but the net loss increased to $12.7 million due to higher operating expenses related to the National OCS Program and commercialization efforts.

TransMedics Group, Inc. reported a 24% decrease in net revenue for the third quarter of 2021, totaling $5.4 million compared to $7.1 million in the third quarter of 2020. This decline was primarily due to the discontinuance of OCS Heart and OCS Liver clinical trial revenue. Despite the revenue decrease, the company achieved two critical milestones with FDA approval of OCS Heart and OCS Liver during the quarter.

TransMedics reported a strong second quarter with a 141% increase in net revenue compared to the previous year. The company achieved key milestones, including positive FDA advisory committee votes for the OCS Liver System and 510(k) clearance of the OCS Lung Solution. Increased operating expenses led to a net loss of $10.7 million.

TransMedics Group, Inc. reported a net revenue of $7.1 million for the first quarter of 2021, a 6% decrease compared to the first quarter of 2020. U.S. net revenue increased by 11% year-over-year. The gross margin was 68% as compared to 65% in the first quarter of 2020. Net loss for the first quarter of 2021 was $7.9 million compared to $8.9 million in the first quarter of 2020.

TransMedics Group, Inc. reported a net revenue of $7.6 million for the fourth quarter of 2020, representing a 26% increase compared to the fourth quarter of 2019. The increase was primarily due to the recovery of U.S. sales led by OCS Lung activities. The net loss for the quarter was $6.3 million, compared to $9.2 million in the same period in 2019.

TransMedics reported a net revenue of $7.1 million for Q3 2020, a 2% decrease compared to Q3 2019. The net loss was $5.1 million, an improvement from the $8.3 million loss in the same quarter of the previous year. The company's gross margin increased to 71%, and operating expenses decreased due to cash preservation efforts.

TransMedics reported a decrease in revenue for the second quarter of 2020 due to the COVID-19 pandemic. However, the company achieved several milestones, including the rescheduling of the OCS Heart FDA Advisory Committee meeting, submission of the OCS Liver PMA to the FDA, and progress in the OCS Heart DCD U.S. clinical program. The company is focused on securing approvals for its OCS products in the U.S. in 2021.

TransMedics reported a strong start to 2020 with a 61% increase in net revenue, driven by OCS adoption in the US and internationally. The company is taking measures to preserve cash and mitigate risks during the COVID-19 pandemic.

TransMedics' net revenue for the fourth quarter of 2019 was $6.1 million, a 71% increase compared to the fourth quarter of 2018. Gross margin for the fourth quarter of 2019 was 62% as compared to 42% in the fourth quarter of 2018. Net loss for the fourth quarter of 2019 was $9.2 million compared to $7.6 million in the fourth quarter of 2018.